Lineage Cell Therapeutics (LCTX) Short Interest Ratio & Short Volume $1.01 -0.01 (-0.98%) As of 07/3/2025 05:00 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock Lineage Cell Therapeutics Short Interest DataLineage Cell Therapeutics (LCTX) has a short interest of 28.73 million shares, representing 17.19% of the float (the number of shares available for trading by the public). This marks a -2.31% decrease in short interest from the previous month. The short interest ratio (days to cover) is 17.1, indicating that it would take 17.1 days of the average trading volume of 1.59 million shares to cover all short positions.Current Short Interest28,730,000 sharesPrevious Short Interest29,410,000 sharesChange Vs. Previous Month-2.31%Dollar Volume Sold Short$23.29 millionShort Interest Ratio17.1 Days to CoverLast Record DateJune 15, 2025Outstanding Shares228,360,000 sharesShort Percent of Float17.19%Today's Trading Volume912,561 sharesAverage Trading Volume1,594,110 sharesToday's Volume Vs. Average57% Short Selling Lineage Cell Therapeutics? Sign up to receive the latest short interest report for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartLCTX Short Interest Over TimeLCTX Days to Cover Over TimeLCTX Percentage of Float Shorted Over Time Lineage Cell Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/15/202528,730,000 shares $23.29 million -2.3%17.2%17.1 $0.81 5/31/202529,410,000 shares $19.44 million -1.8%17.5%20.6 $0.66 5/15/202529,960,000 shares $14.10 million -0.1%17.8%22.2 $0.47 4/30/202530,000,000 shares $14.97 million +5.5%N/A23.4 $0.50 4/15/202528,430,000 shares $12.19 million +6.7%16.9%20.2 $0.43 3/31/202526,640,000 shares $12.03 million +19.3%15.8%17.1 $0.45 3/15/202522,340,000 shares $11.62 million +1.4%13.3%12.1 $0.52 2/28/202522,030,000 shares $12.37 million +2.2%13.1%11.8 $0.56 2/15/202521,550,000 shares $0.00 +1.2%12.8%8.3 $0.00 1/31/202521,300,000 shares $0.00 -21.4%N/A8.3 $0.00 Get the Latest News and Ratings for LCTX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/202527,110,000 shares $0.00 +4.2%N/A11.5 $0.00 12/31/202426,030,000 shares $0.00 +13.5%N/A12 $0.00 12/15/202422,940,000 shares $0.00 +25.1%N/A13.4 $0.00 11/30/202418,340,000 shares $0.00 +13.7%N/A13 $0.00 11/15/202416,130,000 shares $0.00 +1.2%N/A15.1 $0.00 10/31/202415,940,000 shares $0.00 +1.1%N/A36.8 $0.00 10/15/202415,770,000 shares $0.00 +3.6%N/A33.7 $0.00 9/30/202415,220,000 shares $0.00 -2.6%N/A32 $0.00 9/15/202415,630,000 shares $0.00 -1.2%N/A27.1 $0.00 8/31/202415,820,000 shares $0.00 +2.0%N/A25 $0.00 8/15/202415,510,000 shares $0.00 +6.5%N/A19.5 $0.00 7/31/202414,560,000 shares $0.00 No ChangeN/A16.6 $0.00 7/15/202414,560,000 shares $0.00 +12.7%N/A15.3 $0.00 6/30/202412,920,000 shares $0.00 No ChangeN/A12.8 $0.00 6/15/202412,920,000 shares $0.00 +5.4%N/A12 $0.00 5/31/202412,260,000 shares $0.00 -0.9%N/A11 $0.00 5/15/202412,370,000 shares $0.00 +13.5%N/A12.2 $0.00 4/30/202410,900,000 shares $0.00 +3.0%N/A11 $0.00 4/15/202410,580,000 shares $0.00 +1.7%N/A11.2 $0.00 3/31/202410,400,000 shares $0.00 +4.2%N/A11.4 $0.00 3/15/20249,980,000 shares $0.00 +3.7%N/A11.9 $0.00 2/29/20249,620,000 shares $0.00 -4.2%N/A11.5 $0.00 2/15/202410,040,000 shares $0.00 +18.7%N/A13.1 $0.00 1/31/20248,460,000 shares $0.00 +7.4%N/A11.3 $0.00 1/15/20247,880,000 shares $0.00 +13.5%N/A12.7 $0.00 12/31/20236,940,000 shares $0.00 +12.9%N/A11.3 $0.00 12/15/20236,150,000 shares $0.00 -3.5%N/A11.9 $0.00 11/30/20236,370,000 shares $0.00 +6.0%N/A13.4 $0.00 11/15/20236,010,000 shares $0.00 -2.3%N/A13.3 $0.00 10/31/20236,150,000 shares $7.01 million -2.5%N/A14.1 $1.14379 passengers walked away from this (Ad)Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists[See The Details Here] 10/15/20236,310,000 shares $0.00 +1.5%N/A14.2 $0.00 9/30/20236,220,000 shares $0.00 No ChangeN/A13.2 $0.00 9/15/20236,220,000 shares $0.00 +0.7%N/A13.3 $0.00 8/31/20236,180,000 shares $0.00 +1.0%N/A8.1 $0.00 8/15/20236,120,000 shares $0.00 -0.3%N/A7.8 $0.00 7/31/20236,140,000 shares $0.00 -3.6%N/A8.1 $0.00 7/15/20236,370,000 shares $0.00 -1.1%N/A8.6 $0.00 6/30/20236,440,000 shares $0.00 +19.0%N/A9 $0.00 6/15/20235,410,000 shares $0.00 +13.7%N/A7.7 $0.00 5/31/20234,760,000 shares $0.00 +11.5%N/A12.7 $0.00 5/15/20234,270,000 shares $0.00 -6.0%N/A12.8 $0.00 4/30/20234,540,000 shares $0.00 -0.2%N/A12.9 $0.00 4/15/20234,550,000 shares $0.00 +2.9%N/A13 $0.00 3/31/20234,420,000 shares $0.00 +7.3%N/A12.9 $0.00 3/15/20234,120,000 shares $0.00 -1.2%N/A10.9 $0.00 2/28/20234,170,000 shares $0.00 -0.5%N/A11.2 $0.00 2/15/20234,190,000 shares $0.00 +1.0%N/A11.3 $0.00 1/31/20234,150,000 shares $0.00 -0.2%N/A10.5 $0.00 1/15/20234,160,000 shares $0.00 +2.0%N/A10.9 $0.00 12/30/20224,080,000 shares $0.00 -4.0%N/A10.5 $0.00 12/15/20224,250,000 shares $0.00 -1.6%N/A12.5 $0.00 11/30/20224,320,000 shares $0.00 +0.7%N/A13.4 $0.00 11/15/20224,290,000 shares $0.00 -0.2%N/A13.8 $0.00 10/31/20224,300,000 shares $0.00 -3.4%N/A15 $0.00 10/15/20224,450,000 shares $0.00 -0.5%N/A13.9 $0.00 9/30/20224,470,000 shares $0.00 +0.7%N/A14.2 $0.00 9/15/20224,440,000 shares $0.00 -2.8%N/A6.6 $0.00 8/31/20224,570,000 shares $0.00 +2.0%N/A6 $0.00 8/15/20224,480,000 shares $0.00 -7.4%N/A5.3 $0.00 7/31/20224,840,000 shares $0.00 -2.6%N/A5.3 $0.00 7/15/20224,970,000 shares $0.00 -9.3%N/A5.3 $0.00 6/30/20225,480,000 shares $0.00 -38.6%N/A5.4 $0.00 6/15/20228,930,000 shares $0.00 -7.8%N/A8.9 $0.00 5/31/20229,690,000 shares $0.00 -8.3%N/A14 $0.00 5/15/202210,570,000 shares $0.00 +5.0%N/A15.7 $0.00 4/30/202210,070,000 shares $0.00 +12.5%N/A15.7 $0.00 4/15/20228,950,000 shares $0.00 -3.8%N/A13.3 $0.00 3/31/20229,300,000 shares $0.00 +1.8%N/A13 $0.00 3/15/20229,140,000 shares $0.00 +5.2%N/A10.3 $0.00 2/28/20228,690,000 shares $0.00 -3.3%N/A7.6 $0.00 2/15/20228,990,000 shares $0.00 +4.9%N/A7.3 $0.00 1/31/20228,570,000 shares $13.54 million +0.2%N/A6.9 $1.58 1/15/20228,550,000 shares $0.00 +7.7%N/A6.9 $0.00 12/31/20217,940,000 shares $0.00 -23.3%N/A7.1 $0.00 12/15/202110,350,000 shares $0.00 +23.7%N/A9.8 $0.00 11/30/20218,370,000 shares $18.92 million +9.3%N/A10.5 $2.26 11/15/20217,660,000 shares $0.00 -6.6%N/A10.8 $0.00 10/29/20218,200,000 shares $18.70 million No ChangeN/A12.1 $2.28 10/15/20218,200,000 shares $0.00 -6.8%N/A12.6 $0.00 9/30/20218,800,000 shares $0.00 +14.3%N/A12.4 $0.00379 passengers walked away from this (Ad)Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists[See The Details Here] 9/15/20217,700,000 shares $0.00 +1.1%N/A7.4 $0.00 8/31/20217,620,000 shares $0.00 -6.6%N/A7.2 $0.00 8/13/20218,160,000 shares $0.00 -8.0%N/A6.6 $0.00 7/30/20218,870,000 shares $0.00 -2.0%N/A6.8 $0.00 7/15/20219,050,000 shares $0.00 +6.2%5.6%6.4 $0.00 6/30/20218,520,000 shares $0.00 +37.2%5.3%6 $0.00 6/15/20216,210,000 shares $0.00 -3.1%3.9%5.4 $0.00 5/28/20216,410,000 shares $0.00 +2.7%4.0%5.4 $0.00 5/14/20216,240,000 shares $0.00 +13.0%N/A5.2 $0.00 4/30/20215,520,000 shares $0.00 +1.7%N/A3.7 $0.00 4/15/20215,430,000 shares $13.68 million +1.9%N/A3.5 $2.52 3/31/20215,330,000 shares $13.86 million +25.4%N/A2.9 $2.60 3/15/20214,250,000 shares $10.24 million +10.4%N/A2.2 $2.41 2/26/20213,850,000 shares $9.09 million -14.6%2.6%2 $2.36 2/12/20214,510,000 shares $10.19 million -2.0%3.0%2.6 $2.26 1/29/20214,600,000 shares $11.27 million -23.1%3.1%2.9 $2.45 1/15/20215,980,000 shares $17.46 million +7.4%4.0%4.2 $2.92 12/31/20205,570,000 shares $9.69 million -10.7%3.7%4.9 $1.74 12/15/20206,240,000 shares $11.42 million -12.9%4.2%6.1 $1.83 11/30/20207,160,000 shares $10.02 million +1.0%4.8%8.2 $1.40 11/15/20207,090,000 shares $10.42 million -10.8%4.8%8.7 $1.47 10/30/20207,950,000 shares $9.22 million -2.6%5.3%10.6 $1.16 10/15/20208,160,000 shares $11.18 million +12.4%5.5%10.7 $1.37 9/30/20207,260,000 shares $6.80 million +28.0%4.9%10.2 $0.94 9/15/20205,670,000 shares $5.33 million -9.1%3.8%5.9 $0.94 8/31/20206,240,000 shares $5.71 million +7.8%4.2%6.1 $0.92 8/14/20205,790,000 shares $5.33 million -3.8%3.9%4.5 $0.92 7/31/20206,020,000 shares $4.94 million +11.3%4.0%4.7 $0.82 7/15/20205,410,000 shares $4.04 million -1.3%3.6%4.1 $0.75 LCTX Short Interest - Frequently Asked Questions What is Lineage Cell Therapeutics' current short interest? Short interest is the volume of Lineage Cell Therapeutics shares that have been sold short but have not yet been closed out or covered. As of June 15th, traders have sold 28,730,000 shares of LCTX short. 17.19% of Lineage Cell Therapeutics' shares are currently sold short. Learn More on Lineage Cell Therapeutics' current short interest. What is a good short interest ratio for Lineage Cell Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. LCTX shares currently have a short interest ratio of 17.0. Learn More on Lineage Cell Therapeutics's short interest ratio. What is a good short interest percentage for Lineage Cell Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 17.19% of Lineage Cell Therapeutics' floating shares are currently sold short. Is Lineage Cell Therapeutics' short interest increasing or decreasing? Lineage Cell Therapeutics saw a decline in short interest during the month of June. As of June 15th, there was short interest totaling 28,730,000 shares, a decline of 2.3% from the previous total of 29,410,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Lineage Cell Therapeutics' short interest compare to its competitors? 17.19% of Lineage Cell Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Lineage Cell Therapeutics: Zymeworks Inc. (10.16%), ArriVent BioPharma, Inc. (25.85%), Praxis Precision Medicines, Inc. (9.55%), Ardelyx, Inc. (11.98%), LENZ Therapeutics, Inc. (15.60%), Oculis Holding AG (0.07%), Cogent Biosciences, Inc. (15.65%), Syndax Pharmaceuticals, Inc. (26.66%), Chimerix, Inc. (4.27%), Avid Bioservices, Inc. (18.17%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($69.26 billion), Invesco QQQ ($25.22 billion), iShares Russell 2000 ETF ($20.33 billion), iShares 20+ Year Treasury Bond ETF ($9.99 billion), MicroStrategy Incorporated ($9.12 billion), Canadian Natural Resources Limited ($6.73 billion), SPDR S&P Biotech ETF ($6.52 billion), Invesco S&P 500 Equal Weight ETF ($5.60 billion), Financial Select Sector SPDR Fund ($4.64 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.59 billion). View all of the most shorted stocks. What does it mean to sell short Lineage Cell Therapeutics stock? Short selling LCTX is an investing strategy that aims to generate trading profit from Lineage Cell Therapeutics as its price is falling. LCTX shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Lineage Cell Therapeutics? A short squeeze for Lineage Cell Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of LCTX, which in turn drives the price of the stock up even further. How often is Lineage Cell Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LCTX, twice per month. The most recent reporting period available is June, 15 2025. More Short Interest Resources from MarketBeat Related Companies ZYME Short Interest Data AVBP Short Interest Data PRAX Short Interest Data ARDX Short Interest Data LENZ Short Interest Data OCS Short Interest Data COGT Short Interest Data SNDX Short Interest Data CMRX Short Interest Data CDMO Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NYSEAMERICAN:LCTX) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lineage Cell Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lineage Cell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
